



MAUNA KEA TECHNOLOGIES ANNOUNCES CENTERS FOR MEDICARE AND MEDICAID SERVICES SET NEW PHYSICIAN PAYMENTS FOR UPPER GI ENDOSCOPY WITH CELLVIZIO® OPTICAL ENDOMICROSCOPY

Physicians in the United States to be paid for procedures involving Cellvizio based on published rates included in 2014 National Average Physician Fees

ATLANTA, GA - January 13, 2014 – The U.S. Centers for Medicare & Medicaid Services (CMS) recently released 2014 National Average Medicare Physician Fees for upper gastrointestinal (GI) endoscopy procedures with Cellvizio® Optical Confocal Endomicroscopy from Mauna Kea Technologies (NYSE Euronext: MKEA, FR0010609263).

Since January 2013, physician fees related to upper gastrointestinal (GI) endoscopy procedures with Cellvizio® Optical Confocal Endomicroscopy were based on carrier discretion. With the new National Average Physician Fees, physician payments for CPT codes will allow reimbursement for upper GI endoscopy procedures using Cellvizio from public and commercial payers.

“The important news here is that physicians will progressively be paid for upper GI endoscopy procedures with Cellvizio based on rates set by CMS. Endomicroscopy is now widely recognized as a highly effective option for upper GI endoscopy procedures, and this news from CMS provides important further validation of the benefits of endomicroscopy using Cellvizio and the commercial opportunity it presents to both physicians and hospitals,” said Cheryl Soderholm, vice president of healthcare policy and reimbursement at Mauna Kea Technologies.

Additionally, the endomicroscopy CPT codes also include an increase in facility payment rates from \$927 to \$1013 in the 2014 fees.

“These actions by CMS are another example of the expanding support for use of endomicroscopy with Cellvizio as an effective procedure with important advantages for both patients and clinicians. With this milestone, we look forward to continuing our global efforts to extend access to Cellvizio to new healthcare facilities and identifying additional applications for this proven technology in the years ahead,” said Sacha Loiseau, founder and CEO of Mauna Kea Technologies. “

About Mauna Kea Technologies

Mauna Kea Technologies is a global medical device company dedicated to the advent of optical biopsy. The company researches, develops and markets innovative tools to visualize and detect cellular abnormalities during endoscopic procedures. Its flagship product, Cellvizio®, a probe-based Confocal Laser Endomicroscopy (pCLE) system, provides physicians and researchers high-resolution cellular views of tissue inside the body. Large, international, multicenter clinical trials have demonstrated Cellvizio's ability to help physicians more accurately detect early forms of disease and make treatment decisions immediately. Designed to improve patient outcomes and reduce costs within a hospital, Cellvizio can be used with almost any endoscope. Cellvizio has 510(k) clearance from the U.S. Food and Drug Administration and the European CE-Mark for use in the GI tract, biliary and pancreatic ducts and lungs and during fine needle aspiration procedures. Mauna Kea Technologies also obtained CE mark for a complete range of probes dedicated to urology.

For more information on Mauna Kea Technologies, visit www.maunakeatech.com

Mauna Kea Technologies

Eric Cohen
Vice President Finance
Tel: +33 (0)1 70 08 09 70
investor-vpf@maunakeatech.com

France and Europe

NEWCAP
Investor Relations & Financial Communication
Florent Alba / Pierre Laurent
Tel: +33 (0)1 44 71 94 94
maunakea@newcap.fr